CD79A and COVID-19: Although more subjects had detectable levels of anti-spike IgA in saliva (24 of 55 vaccinated or convalescent subjects), there was only a significant difference in frequencies of IgA in saliva between the HIV-1-infected BNT162b2 mRNA vaccinated and the HIV-1-infected COVID-19 convalescent groups.